AstraZeneca's Bold AI Move and UK's IPO Boost Efforts

AstraZeneca signs a significant AI deal to enhance immunology, while UK Chancellor Rachel Reeves focuses on promoting company listings in London. EY narrows its US leadership candidates, as Deloitte refunds a government contract following an AI-related error in a report.

AstraZeneca has entered into a $555 million partnership with Algen Biotechnologies to leverage AI-driven Crispr gene-editing technology for developing cutting-edge therapies in immunology, marking a significant move in the biotech sector.

In a bid to foster the London IPO market, British Chancellor Rachel Reeves is attending JPMorgan's "Tech Stars" event, eyeing tax relief strategies to entice entrepreneurs and boost company listings across the UK.

EY is focused on resolving internal leadership disputes by shortlisting three candidates to head its US operations, while Deloitte faces scrutiny after admitting to inaccuracies in an AI-assisted report, offering a partial refund to the Australian government.

(With inputs from agencies.)